Advancing small molecule program from Hit to Candidate - Webinar by Jubilant Biosys

The project was started with the aim to identify lead series and lead compounds for the inhibition of NNMT to treat metabolic disorders.  The project team faced numerous challenges such as a moderate ADME profile of the starting compounds, establishing biochemical assays for the target and several selectivity assays, establishing target engagement and efficacy models, and such. In this webinar, we will discuss the strategic workflows to overcome such challenges, our project journey, and the swift successful delivery of a lead series and lead compounds. 

Our 4D focused project approach, attributed premier importance to scientific value addition, driving scientific insights about the metabolic therapeutic domain – pharmacological benefits in vivo.  In addition, we offer a platform for all attendants to share their best practices, experience, and bring in their queries.

Takeaways:

• Overcoming Hit to Lead challenges
• Deciding on the best approach 
• Fast-tracking Milestone achievement

To register for the webinar event: https://www.jubilantbiosys.com/advancing-small-molecule-program-from-hit-to-candidate/